BioSino Bio-technology and Science Inc operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BioSino Bio-technology and Science Inc with three other
pharmaceutical manufacturers in Asia:
Guangdong Hybribio Biotech Co Ltd
sales of 398.30 million Chinese Renmimbi [US$57.84 million]
Mizuho Medy Co Ltd
(4.96 billion Japanese Yen [US$44.61 million]
Kainos Laboratories, Inc.
based in Japan
(5.35 billion Japanese Yen [US$48.06 million]
BioSino Bio-technology and Science Inc reported sales of 325.39 million Chinese Renmimbi (US$47.25 million)
December of 2016.
increase of 12.1%
versus 2015, when the company's sales were 290.38 million Chinese Renmimbi.
Sales at BioSino Bio-technology and Science Inc have increased during each of the previous five years
(and since 2011, sales have increased a total of 77%).